Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients.

@article{Wallukat2010DistinctPO,
  title={Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients.},
  author={Gerd Wallukat and Silvia Gilka Mu{\~n}oz Saravia and Annekathrin Haberland and Sabine Bartel and R. Araujo and Gregorio Valda and Diana Duchen and Ivan Diaz Ramirez and Adrian Constantin Borges and Ingolf Schimke},
  journal={Journal of the American College of Cardiology},
  year={2010},
  volume={55 5},
  pages={
          463-8
        }
}
OBJECTIVES Distinguishing the patterns of autoantibodies (AAB) against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon and the discovery of such a pattern in patients who are as yet asymptomatic could help to identify patients at high risk of developing the life-threatening complications of Chagas' disease. BACKGROUND Such AAB against receptors as beta 1 (beta1-AAB), beta 2 (beta2-AAB), and muscarinergic 2 (M2-AAB) are thought to be involved in the pathogenesis of Chagas… Expand
Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon: their potential impact for early risk assessment in asymptomatic Chagas' patients.
We demonstrated in the Journal ([1][1]) that patients with Chagas' disease suffering from cardiomyopathy and megacolon show positivity of autoantibodies directed to the beta1-adrenoreceptor (AAB),Expand
Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies.
TLDR
It is demonstrated here, that the aptamer neutralized, in vitro, the presently known cardiovascular-pathogenic GPCR-AABs, including idiopathic dilated cardiomyopathy, in spontaneously hypertensive rats. Expand
Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study
TLDR
The IMAD trial investigates whether the removal of α1AR-AABs by a 5-day IA procedure has a positive effect (improvement or non-deterioration) on changes of hemodynamic, cognitive, vascular and metabolic parameters in patients with suspected Alzheimer's clinical syndrome within a one-year follow-up period. Expand
Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats
TLDR
The aptamer’s potential for beta1(II)-AAB neutralization and consequently for cardiomyopathy treatment has been shown for the first time in vivo. Expand
Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors.
TLDR
The presented data suggest that aptamer BC 007 might be an appropriate molecule candidate to support future research about the meaning of G-protein-coupled receptor autoantibodies. Expand
The patent situation concerning the treatment of diseases associated with autoantibodies directed against G-protein-coupled receptors.
TLDR
This article provides a short, noncomplete overview about remarkable developmental strategies and technical solutions for the therapy of diseases, associated with G-protein-coupled receptor autoantibodies. Expand
Aptamer Neutralization of Beta1-Adrenoceptor Autoantibodies Isolated From Patients With Cardiomyopathies
TLDR
A specific aptamer that can neutralize cardiomyopathy associated human beta1-AABs in vitro has been identified and characterized, providing a framework for future in vivo testing of this treatment option in animal experiments. Expand
Impairment of agonist-induced M2 muscarinic receptor activation by autoantibodies from chagasic patients with cardiovascular dysautonomia.
TLDR
IgG autoantibodies could function as negative allosteric modulators of acetylcholine-mediated responses, thereby contributing to the development of parasympathetic dysfunction in patients with CD. Expand
Aptamer binding and neutralization of β1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment.
TLDR
The potential of this aptamer for the elimination of β(1)-ECII-AABs and in vivo neutralization is critically analyzed in view of its potential for future use in cardiomyopathy treatment. Expand
Cardiomyopathy - An approach to the autoimmune background.
TLDR
Treatment strategies for "functional autoantibody disease", such as for GPCR-AAB removal (therapeutic plasma exchange, immunoadsorption) and in vivo GPCB attack such as intravenous IgG treatment (IVIG), B-cell depletion and GPCRs binding and neutralization, are critically reflected with respect to their patient benefits. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Interaction of human chagasic IgG with human colon muscarinic acetylcholine receptor: molecular and functional evidence
TLDR
The muscarinic cholinoceptor mediated alteration in distal colon function in chagasic megacolon is considered and autoantibodies that can recognise and activate M2 mAChR are identified. Expand
Role of Neurotransmitter Autoantibodies in the Pathogenesis of Chagasic Peripheral Dysautonomia
TLDR
A strong association between circulating antipeptide M2 mAChR autoantibodies and the presence of patients' low heart rate variablity index, bradycardia and cardiac or esophageal autonomic dysfunction in chronic chagasic patients was verified, making these antipeptic antibodies a proper marker of cardiac neoromyopathy and achalasia. Expand
Structural and functional complexity of the humoral response against the Trypanosoma cruzi ribosomal P2β protein in patients with chronic Chagas’ heart disease
TLDR
High levels of antibodies against the C‐terminus of the Trypanosoma cruzi TcP2β ribosomal protein, defined by the peptide EEEDDDMGFGLFD, named R13, have been measured in sera from patients with chronic Chagas’ Heart Disease, demonstrating that the same parasite antigen may generate antibody specificities with different functional properties. Expand
Functional implications of circulating muscarinic cholinergic receptor autoantibodies in chagasic patients with achalasia.
TLDR
Both the total IgG fraction and anti-M(2)-peptide antibodies increased the basal tone, reduced the relaxant effect of isoproterenol, and decreased cAMP accumulation in esophageal strips, displaying a muscarinic agonist-like activity on M(2) mAChR. Expand
Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications
TLDR
The presence of autoantibodies against the second extracellular loop of the human heart muscarinic acetylcholine receptors (mAChR) in patients with Chagas' disease is reported by using a synthetic 24‐mer peptide in immunoblotting and enzyme im‐munoassay. Expand
Cross-talk between anti-β1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease
TLDR
The hypothesis of a similar origin for anti-receptor antibodies in both diseases is forwarded and the knowledge about the structural basis of receptor-antibody interactions, about their mechanisms of action and about their pathogenicity is summarized. Expand
Cardiac M2 muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia
TLDR
There is an association between circulating antipeptide autoantibodies in chagasic patients and the presence of bradycardia and other dysautonomic symptoms, which support the hypothesis that autoimmune mechanisms play a role in the pathogenesis of chagAsic cardioneuromyopathy. Expand
Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy.
TLDR
The presence of circulating antibodies which bind to beta adrenergic and muscarinic cholinergic receptors of myocardium may partially explain the cardiomyoneuropathy of Chagas' disease, in which the sympathetic and parasympathetic systems are affected. Expand
Pathogenesis of Chronic Chagas Heart Disease
TLDR
Evidence from studies in animal models and in anima nobile points to 4 main pathogenetic mechanisms to explain the development of chronic Chagas heart disease: autonomic nervous system derangements, microvascular disturbances, parasite-dependent myocardial aggression, and immune-mediatedMyocardial injury. Expand
Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy.
TLDR
Evidence is provided that an autoimmune attack directed against the cardiac beta(1)-adrenergic receptor-targeted autoimmune DCM should be categorized with other known receptor Ab-mediated autoimmune diseases, such as Graves disease or myasthenia gravis. Expand
...
1
2
3
...